Acromegaly historical perspective: Difference between revisions
Jump to navigation
Jump to search
| Line 16: | Line 16: | ||
*In 1886, Dr. Pierre Marie named the disease as acromegaly. Dr. Marie reported a patient presented with hypertrophied extremities and he linked between this presentation and acromegaly. | *In 1886, Dr. Pierre Marie named the disease as acromegaly. Dr. Marie reported a patient presented with hypertrophied extremities and he linked between this presentation and acromegaly. | ||
===Landmark Events in the Development of Treatment Strategies=== | ===Landmark Events in the Development of Treatment Strategies=== | ||
*In | *In the 1970s, bromocriptine, a dopamine agonist, was used by Dr. G. Michael Besser to treat acromegaly. Dr. Besser used bromocriptine on some patients and it showed a remarkable improvement in most of the patients. A reduction in the growth hormone was also observed.<ref name="pmid347861">{{cite journal| author=Besser GM, Wass JA, Thorner MO| title=Acromegaly--results of long term treatment with bromocriptine. | journal=Acta Endocrinol Suppl (Copenh) | year= 1978 | volume= 216 | issue= | pages= 187-98 | pmid=347861 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=347861 }} </ref> | ||
*In 1973, Dr. Roger Guillemin and Paul Brazeau discovered somatostatin which is a polypeptide inhibitor of the growth hormone.<ref name="pmid4682131">{{cite journal| author=Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J et al.| title=Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. | journal=Science | year= 1973 | volume= 179 | issue= 4068 | pages= 77-9 | pmid=4682131 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4682131 }}</ref> | |||
*In 1978, somatostatin analogs were developed by Dr. Wylie W. Vale. These somatostatin analogs provide the same inhibitory function and potency of somatostatin against acromegaly.<ref name="pmid210361">{{cite journal| author=Vale W, Rivier J, Ling N, Brown M| title=Biologic and immunologic activities and applications of somatostatin analogs. | journal=Metabolism | year= 1978 | volume= 27 | issue= 9 Suppl 1 | pages= 1391-401 | pmid=210361 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=210361 }}</ref> | |||
===Impact on Cultural History=== | ===Impact on Cultural History=== | ||
Revision as of 19:56, 2 August 2017
|
Acromegaly Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acromegaly historical perspective On the Web |
|
American Roentgen Ray Society Images of Acromegaly historical perspective |
|
Risk calculators and risk factors for Acromegaly historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Historical Perspective
Discovery
- In 1567, Dr. Johannes Wier was the first to describe a case of a giant female patient. Dr. Wier described the course of acromegaly in this patient in his article. Dr. Wier mentioned that she was of normal stature then she began to increase in height and size at age of fourteen. However, she had a normal good life. Dr. Wier also linked between the acromegaly and amenorrhea in this patient.[1]
- In 1772, Dr. Nicolas Saucerotte reported a case which has a clinical presentation linked with acromegaly.[2]
- In 1864, Dr. Andrea Verga reported a case of acromegaly. Dr. Verga reported a patient whose disproportion big face.
- In 1877, Dr. Brigidi reported a case of an actor who presented with chronic bone deformities. On examination, Dr. Bridgi observed large pituitary gland and it was the first description of pituitary adenoma. Dr. Bridgi then linked between the pituitary adenoma and the acromegaly.
- In 1877, Dr. Henri Henrot also reported a case of acromegaly.
- In 1884, Dr. Fritsche and Theodor Klebs also reported a case of acromegaly with pituitary adenoma.
- In 1886, Dr. Pierre Marie named the disease as acromegaly. Dr. Marie reported a patient presented with hypertrophied extremities and he linked between this presentation and acromegaly.
Landmark Events in the Development of Treatment Strategies
- In the 1970s, bromocriptine, a dopamine agonist, was used by Dr. G. Michael Besser to treat acromegaly. Dr. Besser used bromocriptine on some patients and it showed a remarkable improvement in most of the patients. A reduction in the growth hormone was also observed.[3]
- In 1973, Dr. Roger Guillemin and Paul Brazeau discovered somatostatin which is a polypeptide inhibitor of the growth hormone.[4]
- In 1978, somatostatin analogs were developed by Dr. Wylie W. Vale. These somatostatin analogs provide the same inhibitory function and potency of somatostatin against acromegaly.[5]
Impact on Cultural History
Famous Cases
- The following are a few famous cases of disease name:
References
- ↑ de Herder WW (2016). "The History of Acromegaly". Neuroendocrinology. 103 (1): 7–17. doi:10.1159/000371808. PMID 25572320.
- ↑ Pearce JM (2006). "Nicolas Saucerotte: Acromegaly before Pierre Marie". J Hist Neurosci. 15 (3): 269–75. doi:10.1080/09647040500471764. PMID 16887764.
- ↑ Besser GM, Wass JA, Thorner MO (1978). "Acromegaly--results of long term treatment with bromocriptine". Acta Endocrinol Suppl (Copenh). 216: 187–98. PMID 347861.
- ↑ Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J; et al. (1973). "Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone". Science. 179 (4068): 77–9. PMID 4682131.
- ↑ Vale W, Rivier J, Ling N, Brown M (1978). "Biologic and immunologic activities and applications of somatostatin analogs". Metabolism. 27 (9 Suppl 1): 1391–401. PMID 210361.